ImmunoGen — Technical Presentation (December 2020)
17 slides from ImmunoGen's technical presentation, Dec 7, 2020
Slide 1: IMGN632 Investor Call
CONFIDENTIAL 1 IMGN632 Investor Call December 7, 2020 Exhibit 99.2
Slide 2: Forward Looking Statements
CONFIDENTIAL 2 FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen’s expectations related to: the occurrence, timing, and outcome of potential pre-clinical, clinical,
Slide 3: Agenda
CONFIDENTIAL 3 Agenda IMGN632 BPDCN Data Review Path to Full Approval in BPDCN IMGN632 AML Progress Update BPDCN Landscape 1 2 3 4 Concluding Remarks and Q&A 5 BPDCN: blastic plasmacytoid dendritic cell neoplasm; AML: acute myeloid leukemia
Slide 4: BPDCN Landscape and IMGN632 Data at ASH
CONFIDENTIAL 4 BPDCN Landscape and IMGN632 Data at ASH Naveen Pemmaraju, MD MD Anderson Cancer Center Associate Professor, Department of Leukemia IMGN632 Lead BPDCN Investigator
Slide 5: BPDCN Landscape
CONFIDENTIAL 5 BPDCN Landscape • BPDCN is a rare, aggressive hematologic malignancy characterized by historically poor overall survival and limited therapeutic options • Overexpression of CD123 (IL-3Rα) is present in all BPDCN cases, thereby establishing this surface marker as a rational target for
Slide 6: IMGN632: Novel CD123-Targeting ADC Active in BPDCN and AML
CONFIDENTIAL 6 IMGN632: Novel CD123-Targeting ADC Active in BPDCN and AML • Novel Anti-CD123 Antibody – High affinity binding to CD123 – Unique epitope in extracellular domain • Novel IGN Payload (DGN549)1 – DNA-alkylating activity, single strand DNA breaks (vs. double strand) – Uniform drug antibod
Slide 7: ASH 2020 Data: Phase 1/2 Study Patient Characteristics
CONFIDENTIAL 7 ASH 2020 Data: Phase 1/2 801 Study Patient Characteristics (n=29) Age years, median (range) 72y (19-82) Gender, % (n) Male 76% (22) Female 24% (7) Disease, % (n) Compartment involvement Skin 69% (20) Bone marrow 62% (18) Lymph node/visceral 52% (15) Prior/concurrent malignancy 24% (7)
Slide 8: ASH 2020 Data: Phase 1/2 Study Favorable Safety Profile
CONFIDENTIAL 8 ASH 2020 Data: Phase 1/2 801 Study Favorable Safety Profile (n=29) The most common grade ≥3 adverse events (AEs) were thrombocytopenia, febrile neutropenia, and hyperglycemia (10% each) • Rare liver-related AEs: – One (3%) grade ≥3 LFT elevation: grade 3 for >7 days (DLT), resolved –
Slide 9: ASH 2020 Data: Phase 1/2 Study Efficacy in R/R BPDCN
CONFIDENTIAL 9 ASH 2020 Data: Phase 1/2 801 Study Efficacy in R/R BPDCN • In all R/R BPDCN patients: – Overall response rate (ORR) 29% (8/28, 2 CR, 2 CRc*, 1 CRi, 3 PR) – Composite complete remission rate (CCR#) of 18% (5/28) • Importantly, in patients with prior tagraxofusp exposure: – ORR was 31%
Slide 10: ASH 2020 Data: Phase 1/2 Study Time on Treatment and Response
CONFIDENTIAL 10 ASH 2020 Data: Phase 1/2 801 Study Time on Treatment and Response • Responses are often rapid: mean time to response 1.1 months (range 0.7-3.5) • 39% (11/28) remain on treatment • Durable responses seen (up to 9.2 months) without transplant ASH 2020 Oral Presentation; Pemmaraju, N.,
Slide 11: Advancing IMGN632 in BPDCN and Relapsed/Refractory AML
CONFIDENTIAL 11 Advancing IMGN632 in BPDCN and Relapsed/Refractory AML Anna Berkenblit, MD SVP and Chief Medical Officer ImmunoGen
Slide 12: BPDCN Regulatory Update: Path to Full Approval
CONFIDENTIAL 12 BPDCN Regulatory Update: Path to Full Approval TYPE B MEETING HELD WITH FDA THIS QUARTER ALIGNED ON PATH TO FULL APPROVAL IN BPDCN Add a pivotal cohort of up to 20 frontline patients to support a label covering all BPDCN patients SAP designed to exclude null hypothesis of 10% CR/CRc
Slide 13: Path to Full Approval in BPDCN: Pivotal Cohort Design
CONFIDENTIAL 13 Path to Full Approval in BPDCN: 801 Pivotal Cohort Design SINGLE-ARM PIVOTAL COHORT FOR IMGN632 IN FRONTLINE BPDCN BLA IN 2022 TARGET TIMELINES PRIMARY ENDPOINT CR plus CRc SECONDARY ENDPOINT Duration of CR/CRc ENROLLMENT AND KEY ELIGIBILITY Up to 20 frontline patients Includes patie
Slide 14: Path Forward in AML: IMGN632 in Combination
CONFIDENTIAL 14 Path Forward in AML: IMGN632 in Combination ALL REGIMENS ACTIVE NO DLTs in TRIPLET ENROLLING PATIENTS DATA ANTICIPATED M I D 2 0 2 1 DOSE ESCALATION AND EXPANSION COHORTS2 In CD123+ AML patient-derived xenograft models, the triplet combination significantly improved survival compared
Slide 15: Concluding Remarks
CONFIDENTIAL 15 Concluding Remarks Mark Enyedy President and Chief Executive Officer ImmunoGen
Slide 16: IMGN632 Summary
CONFIDENTIAL 16 IMGN632 Summary POTENTIAL BEST-IN-CLASS THERAPEUTIC FOR BPDCN ALIGNED WITH FDA ON PATHWAY TO FULL APPROVAL CONTINUE TO EVALUATE IN COMBINATION IN R/R AML OPPORTUNITY FOR SECOND MARKETED PRODUCT WITHIN 12 MONTHS OF MIRVETUXIMAB LAUNCH
Slide 17: Q&A
CONFIDENTIAL 17 Q&A